XtalPi (2228.HK), a leading AI for Science (AI4S) platform driven by artificial intelligence and robotics, and Sunshine Lake Pharma Co., Ltd., a premier research-driven pharmaceutical leader, today announced a landmark strategic cooperation agreement.
The two companies intend to establish a joint venture that merges XtalPi’s pioneering “AI + Robotics” R&D platform with Sunshine Lake Pharma’s deep expertise in multi-target R&D data, biological insights, and pipeline development. Sunshine Lake Pharma is expected to invest hundreds of millions of RMB into this collaboration. The partnership aims to build an industry-leading AI drug discovery engine and pursue international technology licensing, creating a diversified “co-creation + technical win-win” profit model.
Deep Synergy: From Data to Commercialization
As a leader in Chinese pharmaceutical patents, Sunshine Lake Pharma possesses real-world data assets for over 150 approved drugs and 100 pipeline candidates. XtalPi, serving 17 of the world’s top 20 pharmaceutical companies, brings a unique integration of quantum physics, AI, and robotic experimentation. This partnership is a comprehensive collaboration encompassing “Data-Model-Pipeline-Commercialization.”
By co-developing AI models and automated laboratories, the two companies will create a powerful R&D engine. They will focus on innovative pipelines for autoimmune diseases, achieving a “dual-flywheel” effect: commercializing the underlying technology while fueling the development of high-value new drug candidates.
Infrastructure and Technical Foundation
Automated Laboratories: The partners will deploy large-scale robotic workstation clusters at Sunshine Lake Pharma’s sites to build AI-driven automated labs. This creates a high-efficiency closed loop of “algorithmic prediction and experimental validation,” accumulating high-precision, structured data.
Predictive Modeling: Leveraging Sunshine Lake Pharma’s massive non-clinical datasets and XtalPi’s algorithms, the companies plan to develop an industry-leading Physiologically Based Pharmacokinetic (PB-PK) Large Model to optimize R&D decision-making and improve clinical success rates.
Full-Lifecycle Engine: The joint venture will address complex challenges in difficult-to-drug targets, molecular synthesis, and SAR (Structure-Activity Relationship) analysis, laying the groundwork for continuous value conversion.
Commercialization and Global Reach
Beyond joint pipeline development, the partners will utilize XtalPi’s global commercial network to promote their collaborative technical assets. These include the PB-PK model, the full-lifecycle AI engine, and Sunshine Lake Pharma’s proprietary “HEC-SynAI” (Synthesis Large Model) and “HEC-PharmAI” (Formulation Large Model).
Through a model of “Computing Power + Data Development + Ecosystem Sharing,” the collaboration will open its technological achievements to both academia and industry, exploring new commercial frontiers in “Model-as-a-Service” (MaaS).
“This partnership marks a milestone convergence between China’s top-tier pharmaceutical industry and cutting-edge AI technology,” stated a representative from XtalPi. “By breaking down data silos and lowering the threshold for AI adoption, we are set to reshape the global drug R&D landscape and drive long-term value for both companies.”
About Sunshine Lake Pharma Co., Ltd.
Founded in 2003, Sunshine Lake Pharma is a comprehensive, research-driven pharmaceutical company. With over 150 approved drugs and 100 candidates in development—including nearly 50 Class 1 innovative drugs—it focuses on infectious diseases, chronic illnesses, and oncology. The company consistently ranks among the top 20 for pharmaceutical R&D strength in China and has received numerous accolades, including the China Patent Gold Award.
